Recurrent Glioblastoma Treated with Bevacizumab: Contrast-enhanced T1-weighted Subtraction Maps Improve Tumor Delineation and Aid Prediction of Survival in a Multicenter Clinical Trial
作者： Benjamin M. Ellingson , Hyun J. Kim , Davis C. Woodworth , Whitney B. Pope , Jonathan N. Cloughesy
关键词: Bevacizumab 、 Predictive value of tests 、 Radiology 、 Clinical trial 、 Survival rate 、 Medicine 、 Subtraction 、 Receiver operating characteristic 、 Magnetic resonance imaging 、 Surgery 、 Randomized controlled trial 、 Radiology Nuclear Medicine and imaging
摘要: Multivariate survival analyses, visual observations, and receiver operating characteristic comparisons helped demonstrate that, compared with conventional segmentation, contrast-enhanced T1-weighted subtraction maps of contrast-enhancing lesions produce better stratification high- low-risk patients treated bevacizumab therefore should be used in future clinical trials involving evaluation antiangiogenic therapies brain tumors.
rsna.org
core.ac.uk
sci-hub.se 参考文章(27)
D R Macdonald, T L Cascino, S C Schold, J G Cairncross, Response criteria for phase II studies of supratentorial malignant glioma. Journal of Clinical Oncology. ,vol. 8, pp. 1277- 1280 ,(1990) , 10.1200/JCO.1990.8.7.1277
Akio Ogura, Katsumi Hayakawa, Syouko Yoshida, Fumie Maeda, Fumito Saeki, Ai Syukutani, Use of Dynamic Phase Subtraction (DPS) Map in Dynamic Contrast-Enhanced MRI of the Breast Journal of Computer Assisted Tomography. ,vol. 35, pp. 749- 752 ,(2011) , 10.1097/RCT.0B013E318232FC6C
David Schiff, Benjamin Purow, Bevacizumab in combination with irinotecan for patients with recurrent glioblastoma multiforme. Nature Reviews Clinical Oncology. ,vol. 5, pp. 186- 187 ,(2008) , 10.1038/NCPONC1077
Marc C. Chamberlain, Radiographic patterns of relapse in glioblastoma. Journal of Neuro-oncology. ,vol. 101, pp. 319- 323 ,(2011) , 10.1007/S11060-010-0251-4
A. D. Norden, G. S. Young, K. Setayesh, A. Muzikansky, R. Klufas, G. L. Ross, A. S. Ciampa, L. G. Ebbeling, B. Levy, J. Drappatz, S. Kesari, P. Y. Wen, Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. ,vol. 72, pp. 779- 787 ,(2008) , 10.1212/01.WNL.0000304121.57857.38
DP Harrington, LM Boxt, PD Murray, Digital subtraction angiography: overview of technical principles. American Journal of Roentgenology. ,vol. 139, pp. 781- 786 ,(1982) , 10.2214/AJR.139.4.781
Maurizio Zangari, Louis M. Fink, Francesca Elice, Fenghuang Zhan, Dorothy M. Adcock, Guido J. Tricot, Thrombotic events in patients with cancer receiving antiangiogenesis agents. Journal of Clinical Oncology. ,vol. 27, pp. 4865- 4873 ,(2009) , 10.1200/JCO.2009.22.3875
Andrew D. Norden, Jan Drappatz, Patrick Y. Wen, Antiangiogenic therapies for high-grade glioma. Nature Reviews Neurology. ,vol. 5, pp. 610- 620 ,(2009) , 10.1038/NRNEUROL.2009.159
Jeffrey J. Raizer, Sean Grimm, Marc C. Chamberlain, M. Kelly Nicholas, James P. Chandler, Kenji Muro, Steven Dubner, Alfred W. Rademaker, Jaclyn Renfrow, Markus Bredel, A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer. ,vol. 116, pp. 5297- 5305 ,(2010) , 10.1002/CNCR.25462
Benjamin M. Ellingson, Taryar Zaw, Timothy F. Cloughesy, Kourosh M. Naeini, Shadi Lalezari, Sandy Mong, Albert Lai, Phioanh L. Nghiemphu, Whitney B. Pope, Comparison between intensity normalization techniques for dynamic susceptibility contrast (DSC)-MRI estimates of cerebral blood volume (CBV) in human gliomas. Journal of Magnetic Resonance Imaging. ,vol. 35, pp. 1472- 1477 ,(2012) , 10.1002/JMRI.23600